Krie and Yuan Talk Toxicity Management in Breast Cancer
August 23rd 2021Dr. Krie and Dr. Yuan discussed treatment-related adverse effects one should be aware of and prepared to manage, recommended management strategies for these TRAEs, and important points to emphasize to patients before they begin treatment.
Pal Provides Perspective on Pivotal Trials in RCC and Prostate Cancer
July 27th 2021Insights generated from several trials presented during the 2021 ASCO Annual Meeting in renal cell carcinoma illustrate the importance of evaluating checkpoint inhibitors in earlier stages of disease, quality of life, and long-term outcomes, and other data that point to 2 potential new standards of care in prostate cancer.
Siddiqi Spotlights Latest Data on Optimization of Therapy in Hematologic Malignancies
July 23rd 2021Data presented during the 2021 ASCO Annual Meeting offered insight into the optimization of BTK inhibitors, induction therapy, consolidative therapy, and radiation therapy for patients across the paradigm of hematologic malignancies.
Gaps Persist in Understanding the Fundamentals of Informed Consent
July 14th 2021Within the hierarchy of clinical trials, phase 3 randomized studies remain the gold standard, though some argue that appropriately designed meta-analysis of multiple studies provides even more definitive and meaningful insight.
Oncolytic Virus/CAR T-Cell Therapy Combo Shows Preclinical Potential in Solid Tumors
June 19th 2021City of Hope has entered into a licensing agreement with Imugene Ltd. for the patents covering a combination immunotherapy that enables CD19-directed CAR T-cell therapies to target and eradicate difficult-to-treat solid tumors.
Precision Medicine Presents a Disconnect in Oncology Practice
June 16th 2021Multiple FDA approvals and an increasing number of clinical trials examining molecular target–based therapeutics, including second- or even third-generation drugs against a well-defined target, present an ever-widening array of drugs for routine cancer care based on the discovery of specific molecular targets within the tumor or within the germline.
Mosunetuzumab-Polatuzumab Vedotin Combo Effective, Well Tolerated in R/R B-NHL
June 5th 2021Two cases of cytokine release syndrome occurred during the first cycle of step-up dosing; however, both were considered non-severe and were treated without the need of tocilizumab, admission to the ICU or use of vasopressors.
COVID-19 Vaccination Hesitancy Finds Echo in Cancer Care
June 1st 2021Although the COVID-19 vaccine rollout is unprecedented in speed and scope, the process of postapproval surveillance has been shown to be robust and should serve as a source of reassurance to the public regarding the effectiveness of the initial and follow-up review process.
Reaching Conclusions From Limited Data Holds Pitfalls
May 13th 2021The challenges of assessing COVID-19 vaccines shows that events in the real world may differ from those of a formal objective scientific analysis, especially in a setting where such evaluations of necessity involve very small numbers.